Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Capital Employed (2022 - 2025)

InMed Pharmaceuticals (INM) has 4 years of Return on Capital Employed data on record, last reported at 0.73% in Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 29.0% year-over-year to 0.73%; the TTM value through Dec 2025 reached 0.73%, up 29.0%, while the annual FY2025 figure was 0.67%, 8.0% up from the prior year.
  • Return on Capital Employed reached 0.73% in Q4 2025 per INM's latest filing, down from 0.62% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.52% in Q1 2024 and bottomed at 1.73% in Q3 2022.
  • Average Return on Capital Employed over 4 years is 0.93%, with a median of 0.75% recorded in 2025.
  • Peak YoY movement for Return on Capital Employed: soared 104bps in 2023, then crashed -64bps in 2025.
  • A 4-year view of Return on Capital Employed shows it stood at 1.19% in 2022, then soared by 48bps to 0.62% in 2023, then plummeted by -66bps to 1.02% in 2024, then grew by 29bps to 0.73% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.73% in Q4 2025, 0.62% in Q3 2025, and 0.75% in Q2 2025.